Stage IVA EGFR L858R lung adenocarcinoma with malignant effusions and thrombosis

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 21 L858R mutation; TTF-1 weak positive; Napsin A positive; p40 negative; Ki-67 about 10%

Metastatic Site: malignant pleural effusion; malignant pericardial…

As of May 2025, abdominal pain had resolved, splenic infarction had not progressed, thromboembolic events were regressing, no new thrombus formation was seen, and outpatient follow-up continued while he remained on cancer and anticoagulation management.

PubMed CentralRead more →

Extensive-stage small cell lung cancer with brain and adrenal progression after prolonged disease control

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Small-cell lung cancer markers included CD56, CgA and TTF-1; Ki-67 was 80%.

Metastatic Site: brain, right adrenal gland, left adrenal gland

After 31 months of stability on second-line anlotinib with palliative chemoradiotherapy, disease progressed in July 2024 with new brain lesions and adrenal progression; the patient declined additional systemic options and continued anlotinib.

PubMed CentralRead more →

Metastatic NSCLC with ATM mutations: 28-month response to olaparib before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: cfDNA showed ATM and ATM mutations. Common NSCLC drivers were negative; initial tumor markers were negative.

Metastatic Site: liver, left pubic bone, bilateral pulmonary nodules,…

After 28 months of remission and improved quality of life on olaparib, June 2024 PET-CT showed progression with a new 1.2 cm hypermetabolic left lower-lobe pulmonary nodule; olaparib was still being continued at the October 2024 clinic visit.

PubMed CentralRead more →

Stage IIIA squamous lung cancer with pathologic complete response after immunochemotherapy

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: PD-L1 TPS 90%; PD-L1 CPS 100%; EGFR p.G719S 24.9%; EGFR p.S768I 24.6%; TP53 p.S183* 7.2%; TMB 0.0 Muts/Mb

Systematic imaging in March 2025 showed no recurrence or metastasis, with postoperative disease-free survival longer than 30 months and overall survival longer than 34 months.

PubMed CentralRead more →

Stage IV Large-Cell Neuroendocrine Lung Cancer Controlled for Nearly Four Years With Multiple Treatments

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: PD-L1 high initially; no actionable driver mutation; later PD-L1 5%

Metastatic Site: liver, bones

After several partial responses across multiple treatment lines, she entered hospice and died on December 13, 2024, after an overall survival of 47 months.

PubMed CentralRead more →

Stage II EGFR Lung Cancer: Samantha's Patient Story

Patient Info: Samantha Vaughn, Female | Stage II

Biomarkers: EGFR mutation

Samantha had Stage II EGFR-mutated lung cancer removed surgically and was receiving post-operative daily Tagrisso through a clinical trial. As of June 2025, she reported clear results so far but remained on active targeted therapy.

The Patient StoryRead more →

Stage IVA lung adenosquamous carcinoma: complete response after paclitaxel, nedaplatin, and tislelizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Adenosquamous lung cancer markers; PD-L1 TPS 18%; KRAS, BRAF, PIK3CA, FLT1 mutation; TMB 3.7

Metastatic Site: pleura/chest wall, cervical lymph nodes, axillary…

As of March 30, 2025, he maintained complete response with normal tumor markers, no radiologic evidence of progression or recurrence, and progression-free survival of 46.5 months after paclitaxel/nedaplatin/tislelizumab followed by maintenance tislelizumab.

PubMed CentralRead more →

Aggressive Lung Squamous Cell Carcinoma With Tumor Extension Into the Heart

Patient Info: Anonymized, male, 50s

Biomarkers: PD-L1 high

The cancer progressed rapidly despite treatment, and he died 3 months after diagnosis and 2 months after starting chemotherapy and pembrolizumab.

PubMed CentralRead more →

Limited-stage small cell lung cancer with no recurrence after 14 years

Patient Info: Anonymized, Female, 60s

Biomarkers: SCLC markers: CD56/TTF-1 positive. Essential thrombocythemia had JAK2 . Cancer predisposition gene testing was negative.

More than 14 years after limited-stage SCLC diagnosis, surveillance imaging confirmed no recurrence, while essential thrombocythemia remained controlled with weekly Pegasys.

PubMed CentralRead more →

Stage III Lung Cancer: Alexis's Survivor Story

Patient Info: Alexis, Female, Under 40 | Stage III

Biomarkers: No lung tumor biomarker reported

Alexis had Stage III pulmonary neuroendocrine/carcinoid cancer treated with removal of the entire left lung and 4 months of adjuvant pill chemotherapy. Follow-up scans after chemotherapy were clear, and her doctor called the status no evidence of disease; she continues long-term surveillance.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Jenny's Patient Story

Patient Info: Jenny Apple, Female | Stage IV

Biomarkers: EGFR exon 20 mutation

Metastatic Site: brain

Jenny Apple had nonsmoking lung adenocarcinoma with an EGFR exon 20 mutation. Her cancer was first found at Stage IIIA / near IIIB and later progressed to Stage IV with brain metastases. She died before the June 2025 story from her husband Kyle.

The Patient StoryRead more →

Stage I Pleomorphic Lung Cancer Recurring With Bone Metastasis Within Five Months

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 high; no detected driver mutation

Metastatic Site: bone

PET-CT in December 2024 showed a partial response. As of February 2025, he remained on sintilimab and bevacizumab maintenance with about 9 months of progression-free survival after recurrence treatment.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma With KRAS Mutation Responding to Immunotherapy and Anti-Angiogenic Treatment

Patient Info: Anonymized, male | Stage IV

Biomarkers: KRAS mutation; MET amplification

Metastatic Site: pleura

By the December 2023 follow-up, the pleural effusion had disappeared, the primary lung tumor had not progressed, and he was described as symptom-free and in good health on maintenance treatment.

PubMed CentralRead more →

ALK-rearranged lung adenocarcinoma: sustained partial response on reduced-dose crizotinib after renal cysts

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK gene translocation positive in >15% of tumor cells by FISH

As of June 2025, the lung cancer remained in partial response without progression on reduced-dose crizotinib, while crizotinib-associated renal cysts had markedly regressed.

PubMed CentralRead more →

Lung Cancer Responds to Chemo-Immunotherapy Despite a Benign Liver Pseudotumor

Patient Info: Anonymized, male, 60s

After immunotherapy was stopped, follow-up scans continued to show a partial response in the lung cancer, and he remained clinically stable at the latest follow-up.

PubMed CentralRead more →

Stage 1 lung adenocarcinoma: complete response to cryoablation

Patient Info: Anonymized, Male, 70+

Biomarkers: Not reported for this patient

Two years after cryoablation, he remained clinically stable with no signs of local recurrence or distant metastasis.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Alisa's Patient Story

Patient Info: Alisa Secaida, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Brain; lymph nodes

As of May 2025, after alectinib and lung surgery, pathology still showed active tumor and lymph-node cancer cells, and Alisa was receiving IMRT for remaining disease.

City of HopeRead more →

Small-cell lung cancer: complete response complicated by radiation bronchial injury and adrenal recurrence

Patient Info: Anonymized, Male, 40s | Stage IV

Metastatic Site: left adrenal gland

As of May 2025, the initial lung and mediastinal disease had achieved complete response, but the patient developed severe radiation-related bronchial injury and later left adrenal metastasis requiring renewed systemic chemotherapy.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Recurring After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified initially; recurrent tumor PD-L1 >50%

The cancer recurred in June 2024 with a para-aortic mass and enlarged mediastinal and supraclavicular lymph nodes. Camrelizumab was started, but he could not tolerate it and declined further treatment.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified; PD-L1 at least 1%

No signs of recurrence were observed through April 2025 after surgery and 4 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Natasha's Patient Story

Patient Info: Natasha, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: brain

Natasha had Stage IV EGFR-positive lung cancer with brain metastases. Tagrisso/osimertinib was her main treatment, but a new brain metastasis later appeared and was treated with Gamma Knife. As of May 2025, she was awaiting follow-up MRI while continuing care.

The Patient StoryRead more →

Small-cell lung cancer with anti-GABAb paraneoplastic limbic encephalitis: complete response after radiochemotherapy

Patient Info: Anonymized, Female, 70+

Biomarkers: CSF anti-GABAb antibodies positive

As of May 2025, follow-up imaging after combined radiochemotherapy showed complete resolution of the right hilar lung mass and right medial temporal hypermetabolism, and the patient had no further seizures.

PubMed CentralRead more →

Localized sarcomatoid lung carcinoma: no recurrence 14 months after lobectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported; histopathology confirmed sarcomatoid carcinoma

As of May 2025, the patient remained in good health with no evidence of recurrence 14 months after video-assisted thoracoscopic left lower lobectomy.

PubMed CentralRead more →

Localized lung neuroendocrine tumor/carcinoid: wedge resection after surveillance

Patient Info: Anonymized, Female, 50s

Biomarkers: Well-differentiated neuroendocrine tumor, grade I; no lung molecular biomarkers reported

As of May 2025, the localized left lung carcinoid had remained stable during surveillance and was removed by thoracotomy with wedge resection; no lung metastasis was reported.

PubMed CentralRead more →